Related Experiment Video
Updated: Jul 6, 2025
Scleral Cross-linking Using Riboflavin and Ultraviolet-A Radiation for Prevention of Axial Myopia in a Rabbit Model
Published on: April 3, 2016
Outcomes of Strabismus Surgery Following Teprotumumab Therapy
Grant Hilliard1, Jaron Pruett2, Sean P Donahue2
1From the Department of Ophthalmology, Hamilton Eye Institute, The University of Tennessee Health Science Center (G.H., L.C.D, M.E.H., N.C.K.), Memphis, Tennessee.
Purpose:
To investigate the results of patients undergoing surgical treatment for strabismic diplopia in thyroid eye disease (TED) following teprotumumab.
Design:
Multicenter, retrospective, case series.
Methods:
We report 28 patients who underwent extraocular muscle surgery for strabismic diplopia after treatment with teprotumumab at 7 different academic centers. Elapsed time from last teprotumumab dose to the date of surgery, previous orbital decompression, primary preoperative horizontal and vertical deviation, surgical procedure, and 2-month postoperative results were collected from the patient records.
Results:
Sixteen (57%) patients were diplopia-free after 1 surgery. Three (11%) chose prism spectacles to correct residual diplopia, 2 (7%) used compensatory head posture to resolve diplopia, and 1 (4%) had intermittent diplopia and was functionally improved (choosing no prisms or further surgery). These were considered treatment successes. Three (11%) patients required reoperation, and all were diplopia-free after their second procedure.
Conclusions:
Most patients requiring surgery for strabismic diplopia following teprotumumab achieve good outcomes with success rates comparable to series published before the availability of teprotumumab.
